Studies found that the anti-TRAIL antibody treatment of rodents with established PAH-reversed pulmonary vascular remodeling by reducing proliferation and inducing apoptosis, improved hemodynamic indices, and significantly increased survival (Hameed et al., 2012). This evidence concerns the gene TNFSF10 and pulmonary arterial hypertension.